entertainment -WSS

entertainment

author：comprehensive 2025-09-29 16:34:22 - browse：28

Lung cancer under microscope — coverage from STAT — Lung cancer Adobe

CHICAGO — Delfi Diagnostics, a company seeking to develop liquid biopsy tests to help screen for lung cancer, published a scientific paper on Monday describing key aspects of the test and unveiled the design of a key clinical trial.

Delfi also announced that the Merck Global Health Innovation Fund, the VC arm of the drug giant, has made an investment of an undisclosed amount in the company.

Unlike Grail, a unit of Illumina, or Exact Sciences, which seeks to develop a blood test that can be used to screen for multiple types of cancer, Delfi is focusing on a single disease — lung cancer — in which the utility of screening with existing technology is not in dispute. Using low-dose CT scans to detect lung cancer is considered an established technology for people at higher risk of lung cancer. However, far too few people get screened.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Popular nasal decongestant doesn't actually relieve congestion

WSS

What PEPFAR has meant on the ground in Ukraine

How medical schools plan to diversify without affirmative action

Pfizer plans to depart BIO

Telehealth for opioid use disorder is lifesaving

WATCH: Why do bright lights make us see spots?

Pig kidney works a record two months in donated body

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Medicare proposal to cover medical devices draws a mixed reaction

Hospitals consider fixing cancer drug shortages on their own

Dobbs anniversary: the lost opportunity of abortion as health care

FDA approves updated Covid vaccines

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

How housing is health care on Long Island

The cancer drug shortage isn’t new — and neither are the solutions

Radiology is caught between AI's potential and concern for patients

Medicare details structure of new drug price negotiation program

Acelyrin, a rare IPO success, stumbles in its first big test

leisure time

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Acelyrin, a rare IPO success, stumbles in its first big test

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Pfizer plans to depart BIO

What PEPFAR has meant on the ground in Ukraine

What PEPFAR has meant on the ground in Ukraine

Wikipedia

hotspot

focus

explore